Aurobindo, a large generic drug maker, has temporarily halted some production in India after U.S. inspectors found quality-control issues at one of its key facilities. The inspection identified nine issues at the plant in Telangana, prompting the company to stop production on some lines. Aurobindo plans to fix the problems with the help of consultants and hopes to restart production soon. The company believes there will not be a significant impact on its business, but no specific timetable was provided for when production will resume. This episode raises concerns about shortages and the quality of medicines produced by some suppliers.
Source link
Aurobindo cuts production at a key facility amid shortage concerns
